547 related articles for article (PubMed ID: 17145499)
1. SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes.
Fertleman CR; Baker MD; Parker KA; Moffatt S; Elmslie FV; Abrahamsen B; Ostman J; Klugbauer N; Wood JN; Gardiner RM; Rees M
Neuron; 2006 Dec; 52(5):767-74. PubMed ID: 17145499
[TBL] [Abstract][Full Text] [Related]
2. Painful channels.
Catterall WA; Yu FH
Neuron; 2006 Dec; 52(5):743-4. PubMed ID: 17145494
[TBL] [Abstract][Full Text] [Related]
3. Congenital insensitivity to pain: novel SCN9A missense and in-frame deletion mutations.
Cox JJ; Sheynin J; Shorer Z; Reimann F; Nicholas AK; Zubovic L; Baralle M; Wraige E; Manor E; Levy J; Woods CG; Parvari R
Hum Mutat; 2010 Sep; 31(9):E1670-86. PubMed ID: 20635406
[TBL] [Abstract][Full Text] [Related]
4. Paroxysmal extreme pain disorder: a molecular lesion of peripheral neurons.
Choi JS; Boralevi F; Brissaud O; Sánchez-Martín J; Te Morsche RH; Dib-Hajj SD; Drenth JP; Waxman SG
Nat Rev Neurol; 2011 Jan; 7(1):51-5. PubMed ID: 21079636
[TBL] [Abstract][Full Text] [Related]
5. Paroxysmal extreme pain disorder M1627K mutation in human Nav1.7 renders DRG neurons hyperexcitable.
Dib-Hajj SD; Estacion M; Jarecki BW; Tyrrell L; Fischer TZ; Lawden M; Cummins TR; Waxman SG
Mol Pain; 2008 Sep; 4():37. PubMed ID: 18803825
[TBL] [Abstract][Full Text] [Related]
6. NaV1.7 gain-of-function mutations as a continuum: A1632E displays physiological changes associated with erythromelalgia and paroxysmal extreme pain disorder mutations and produces symptoms of both disorders.
Estacion M; Dib-Hajj SD; Benke PJ; Te Morsche RH; Eastman EM; Macala LJ; Drenth JP; Waxman SG
J Neurosci; 2008 Oct; 28(43):11079-88. PubMed ID: 18945915
[TBL] [Abstract][Full Text] [Related]
7. Chronic non-paroxysmal neuropathic pain - Novel phenotype of mutation in the sodium channel SCN9A gene.
Dabby R; Sadeh M; Gilad R; Lampl Y; Cohen S; Inbar S; Leshinsky-Silver E
J Neurol Sci; 2011 Feb; 301(1-2):90-2. PubMed ID: 21094958
[TBL] [Abstract][Full Text] [Related]
8. Paroxysmal extreme pain disorder mutations within the D3/S4-S5 linker of Nav1.7 cause moderate destabilization of fast inactivation.
Jarecki BW; Sheets PL; Jackson JO; Cummins TR
J Physiol; 2008 Sep; 586(17):4137-53. PubMed ID: 18599537
[TBL] [Abstract][Full Text] [Related]
9. Novel SCN9A mutations underlying extreme pain phenotypes: unexpected electrophysiological and clinical phenotype correlations.
Emery EC; Habib AM; Cox JJ; Nicholas AK; Gribble FM; Woods CG; Reimann F
J Neurosci; 2015 May; 35(20):7674-81. PubMed ID: 25995458
[TBL] [Abstract][Full Text] [Related]
10. Mutations at opposite ends of the DIII/S4-S5 linker of sodium channel Na V 1.7 produce distinct pain disorders.
Cheng X; Dib-Hajj SD; Tyrrell L; Wright DA; Fischer TZ; Waxman SG
Mol Pain; 2010 Apr; 6():24. PubMed ID: 20429905
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Navβ4 peptide-mediated resurgent sodium currents in Nav1.7 channels by carbamazepine, riluzole, and anandamide.
Theile JW; Cummins TR
Mol Pharmacol; 2011 Oct; 80(4):724-34. PubMed ID: 21788423
[TBL] [Abstract][Full Text] [Related]
12. Primary erythermalgia as a sodium channelopathy: screening for SCN9A mutations: exclusion of a causal role of SCN10A and SCN11A.
Drenth JP; Te Morsche RH; Mansour S; Mortimer PS
Arch Dermatol; 2008 Mar; 144(3):320-4. PubMed ID: 18347287
[TBL] [Abstract][Full Text] [Related]
13. p.L1612P, a novel voltage-gated sodium channel Nav1.7 mutation inducing a cold sensitive paroxysmal extreme pain disorder.
Suter MR; Bhuiyan ZA; Laedermann CJ; Kuntzer T; Schaller M; Stauffacher MW; Roulet E; Abriel H; Decosterd I; Wider C
Anesthesiology; 2015 Feb; 122(2):414-23. PubMed ID: 25285947
[TBL] [Abstract][Full Text] [Related]
14. Nav1.7 mutations associated with paroxysmal extreme pain disorder, but not erythromelalgia, enhance Navbeta4 peptide-mediated resurgent sodium currents.
Theile JW; Jarecki BW; Piekarz AD; Cummins TR
J Physiol; 2011 Feb; 589(Pt 3):597-608. PubMed ID: 21115638
[TBL] [Abstract][Full Text] [Related]
15. Intra- and interfamily phenotypic diversity in pain syndromes associated with a gain-of-function variant of NaV1.7.
Estacion M; Han C; Choi JS; Hoeijmakers JG; Lauria G; Drenth JP; Gerrits MM; Dib-Hajj SD; Faber CG; Merkies IS; Waxman SG
Mol Pain; 2011 Dec; 7():92. PubMed ID: 22136189
[TBL] [Abstract][Full Text] [Related]
16. A novel SCN9A gene variant identified in a Chinese girl with paroxysmal extreme pain disorder (PEPD): a rare case report.
Hua Y; Cui D; Han L; Xu L; Mao S; Yang C; Gao F; Yuan Z
BMC Med Genomics; 2022 Jul; 15(1):159. PubMed ID: 35840956
[TBL] [Abstract][Full Text] [Related]
17. A novel SCN9A mutation responsible for primary erythromelalgia and is resistant to the treatment of sodium channel blockers.
Wu MT; Huang PY; Yen CT; Chen CC; Lee MJ
PLoS One; 2013; 8(1):e55212. PubMed ID: 23383113
[TBL] [Abstract][Full Text] [Related]
18. No mutations in the voltage-gated NaV1.7 sodium channel alpha1 subunit gene SCN9A in familial complex regional pain syndrome.
de Rooij AM; Gosso MF; Alsina-Sanchis E; Marinus J; van Hilten JJ; van den Maagdenberg AM
Eur J Neurol; 2010 Jun; 17(6):808-14. PubMed ID: 20074229
[TBL] [Abstract][Full Text] [Related]
19. An SCN9A channelopathy causes congenital inability to experience pain.
Cox JJ; Reimann F; Nicholas AK; Thornton G; Roberts E; Springell K; Karbani G; Jafri H; Mannan J; Raashid Y; Al-Gazali L; Hamamy H; Valente EM; Gorman S; Williams R; McHale DP; Wood JN; Gribble FM; Woods CG
Nature; 2006 Dec; 444(7121):894-8. PubMed ID: 17167479
[TBL] [Abstract][Full Text] [Related]
20. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia.
Yang Y; Wang Y; Li S; Xu Z; Li H; Ma L; Fan J; Bu D; Liu B; Fan Z; Wu G; Jin J; Ding B; Zhu X; Shen Y
J Med Genet; 2004 Mar; 41(3):171-4. PubMed ID: 14985375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
